Nabriva Therapeutics PLC
Change company Symbol lookup
Select an option...
NBRV Nabriva Therapeutics PLC
HRB H & R Block Inc
GM General Motors Co
NDAQ Nasdaq Inc
DYYXF DB Commodity Double Long ETN
KIQ Kelso Technologies Inc
MMM 3M Co
CBOE Cboe Global Markets Inc
PFE Pfizer Inc
DOW Dow Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Pharmaceuticals | Small Cap Growth
Based in Ireland
Company profile

Nabriva Therapeutics plc is a biopharmaceutical company engaged in the commercialization and development of anti-infective agents to treat serious infections. The Company’s product XENLETA (lefamulin), is a semi-synthetic pleuromutilin antibiotic for systematic administration in humans. It inhibits the synthesis of bacterial protein, which is required for bacteria to grow by binding with high affinity, high specificity and at molecular targets that are different than other antibiotic classes. The Company is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.

Price
Delayed
$0.6259
Day's Change
-0.0357 (-5.40%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.6599
Day's Low
0.6001
Volume
(Heavy Day)

Today's volume of 1,975,247 shares is on pace to be much greater than NBRV's 10-day average volume of 2,903,555 shares.

1,975,247

Gilead announces non-U.S. deals with five generic drugmakers for remdesivir

2:55 pm ET May 12, 2020 (MarketWatch)
Print

Shares of Gilead Sciences Inc. (GILD) were down 1.2% in trading on Tuesday after the drugmaker listed on its website five generic drugmakers that will produce remdesivir, its experimental COVID-19 treatment. The non-exclusive voluntary licensing agreements are with Cipla Ltd. , Ferozsons Laboratories Ltd. , Hetero Labs Ltd., Jubilant Life Sciences Ltd. and Mylan (MYL), to manufacture remdesivir in 127 countries. The Food and Drug Administration recently granted an emergency authorization (http://www.marketwatch.com/story/how-gileads-remdesivir-became-the-leader-in-the-rush-to-find-a-treatment-for-covid-19-2020-05-01) to remdesivir in the U.S. as a treatment for severely ill COVID-19 patients; it has also been approved in Japan. Neither nation is part of these manufacturing agreements. China, where the virus was first detected in 2019, also isn't listed. Gilead said the licenses will be considered royalty-free until one of two things happens: the World Health Organization lifts its public health emergency of international concern declaration, or another drug or vaccine is approved. Gilead's stock is up 22.8% year-to-date. The S&P 500 is down 9.3%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

May 12, 2020 14:55 ET (18:55 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.